PeptideOS
← Library

5-Amino-1MQ

Small-molecule NNMT inhibitor

Also known as: 5-amino-1-methylquinolinium, 5-amino-1-methylquinolinium iodide

Tier 3, Preclinical only

Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.

Half-life
Not established

No human or animal half-life located in an allowed primary source. MW 159.21 is the 5-amino-1-methylquinolinium cation (PubChem); the research material is commonly the iodide salt (higher formula weight).

Dosing
No established dose

Dosed by body weight in mice: ~20 mg/kg subcutaneously three times daily in diet-induced obese mouse studies. Kept as mg/kg per instructions; no back-calculation. No established human dose.

Regulatory status
Not approved. Preclinical research compound (NNMT inhibitor); no human clinical trials with published outcomes.
Evidence base
animal only · confidence: low

Rodent obesity/metabolic studies only; no human data. Evidence overwhelmingly preclinical.

Safety

No human safety data. Preclinical only; safety in humans is unestablished. Not for clinical dosing decisions.